The treatment of patients with asthma and comorbidity
| Autor: | T. V. Bezditko, G. V. Yeryomenko |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Budesonide
medicine.medical_specialty diabetes mellitus type 2 medicine.medical_treatment L-arginine lcsh:Medicine von Willebrand factor Von Willebrand factor Internal medicine Diabetes mellitus Fibrinolysis medicine asthma diabetes mellitus type 2 MCP-1 MMP-9 von Willebrand factor L-arginine Tiotropium bromide Asthma biology business.industry lcsh:R General Medicine Tiotropium bromide asthma medicine.disease Comorbidity Metformin biology.protein business MMP-9 medicine.drug MCP-1 |
| Zdroj: | Medičnì Perspektivi, Vol 23, Iss 1(part1), Pp 50-59 (2018) |
| ISSN: | 2307-0404 |
| Popis: | The increasing prevalence of asthma (A) and diabetes mellitus type 2 (DM2T) necessitates administration of the adequate antiasthmatic long-term basic therapy with consideration of comorbid states. The purpose consisted in revealing the therapeutic potential of Tiotropium bromide (TB) and L-arginine (Tivortine) in patients having uncontrolled moderately severe asthma in combination with DM2T (A+DM2T). Forty seven A+DM2T patients underwent an in-depth study before and after their treatment. They were divided into 2 groups: treatment (group 1, n=28) and comparison (group 2, n=19). Both groups received the standard 2-component therapy: budesonide/formoterol fumarate dihydrate – 160/4.5µg by 2 breaths twice a day and metformin at a dose of 500 mg twice a day. The complex of their basic therapy for group 1 additionally included TB (18 µg a day) and arginine hydrochloride preparation (Tivortine® aspartate, Yuriya-Farm) orally by 15 ml twice a day during 3 months (90 days). The patients were followed up 3 months and one year later. Their general condition demonstrated positive dynamics in both groups, the number of exacerbations in group 1 reducing by a factor of 4. The complex use of L-arginine and TB preparations against a background of the basic therapy in A+DM2T patients produced a better control over the disease, a more rapid elimination of obstruction manifestations, achievement and prolongation of the clinical spirographic remission, an improvement of the quality of life, correction of disturbances in haemocoagulation, fibrinolysis and the functional state of endothelium. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|